Linked Life Data

18630457

Source:http://linkedlifedata.com/resource/pubmed/id/18630457

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3B
pubmed:dateCreated
2008-7-17
pubmed:abstractText
Darbepoetin alfa, has a longer halflife than epoetin alfa (rHuEPO) due to its increased sialylated carbohydrate content and can be administered less frequently. Its advantage in terms of response is not entirely clear.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0250-7005
pubmed:author
pubmed:issnType
Print
pubmed:volume
28
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1767-71
pubmed:meshHeading
pubmed:articleTitle
Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT).
pubmed:affiliation
Department of Medical Oncology, San Giovanni Hospital, Rome, Italy.
pubmed:publicationType
Journal Article, Clinical Trial